Lori A Erickson

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi Malignant basomelanocytic tumor manifesting as metastatic melanoma
    Lori A Erickson
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 28:1393-6. 2004
  2. ncbi Cystic adrenal neoplasms
    Lori A Erickson
    Department of Laboratory Medicine and Pathology Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 101:1537-44. 2004
  3. ncbi Practical markers used in the diagnosis of endocrine tumors
    Lori A Erickson
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Adv Anat Pathol 11:175-89. 2004
  4. ncbi Analysis of parathyroid neoplasms by interphase fluorescence in situ hybridization
    Lori A Erickson
    Department of Laboratory Medicine and Pathology, Anatomic Pathology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Surg Pathol 28:578-84. 2004
  5. ncbi Merkel cell carcinomas: expression of S-phase kinase-associated protein 2 (Skp2), p27, and proliferation markers
    Lori A Erickson
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Endocr Pathol 14:221-29. 2003
  6. ncbi Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas
    Lori A Erickson
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 109:1965-71. 2007
  7. ncbi Characterization of the functional and growth properties of cell lines established from ileal and rectal carcinoid tumors
    Gail A Stilling
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocr Pathol 18:223-32. 2007
  8. ncbi Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment
    Svetomir N Markovic
    Division of Hematology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:490-513. 2007
  9. ncbi Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors
    He Yu Zhang
    Department of Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocrine 30:299-306. 2006
  10. ncbi Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma
    Nobuki Nakamura
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocr Pathol 17:213-23. 2006

Detail Information

Publications38

  1. ncbi Malignant basomelanocytic tumor manifesting as metastatic melanoma
    Lori A Erickson
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 28:1393-6. 2004
    ..A second population of cells was strongly immunoreactive for keratin (wide-spectrum polyclonal antibody) and BerEp4. To our knowledge, this is the first description of a malignant basomelanocytic tumor complicated by metastatic melanoma...
  2. ncbi Cystic adrenal neoplasms
    Lori A Erickson
    Department of Laboratory Medicine and Pathology Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 101:1537-44. 2004
    ..Cystic lesions of the adrenal gland are uncommon and demonstrate a spectrum of histologic changes and may vary from pseudocysts to malignant cystic neoplasms...
  3. ncbi Practical markers used in the diagnosis of endocrine tumors
    Lori A Erickson
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Adv Anat Pathol 11:175-89. 2004
    ..This article reviews the common markers used to characterize endocrine tumors and to recognize tumors involved in the differential diagnosis of specific lesions...
  4. ncbi Analysis of parathyroid neoplasms by interphase fluorescence in situ hybridization
    Lori A Erickson
    Department of Laboratory Medicine and Pathology, Anatomic Pathology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Surg Pathol 28:578-84. 2004
    ..These results indicate that gain of chromosome 11 is associated with more aggressive biologic behavior in parathyroid neoplasms...
  5. ncbi Merkel cell carcinomas: expression of S-phase kinase-associated protein 2 (Skp2), p27, and proliferation markers
    Lori A Erickson
    Department of Laboratory Medicine and Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Endocr Pathol 14:221-29. 2003
    ....
  6. ncbi Clinicopathologic features and BRAF(V600E) mutation analysis in cutaneous metastases from well-differentiated thyroid carcinomas
    Lori A Erickson
    Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Cancer 109:1965-71. 2007
    ..A series of 16 cutaneous metastases were analyzed from well-differentiated thyroid carcinomas to learn more about the clinicopathologic features and BRAF(V600E) mutation status...
  7. ncbi Characterization of the functional and growth properties of cell lines established from ileal and rectal carcinoid tumors
    Gail A Stilling
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocr Pathol 18:223-32. 2007
    ..These results indicate that these carcinoid cell lines can be used to study the proliferative and apoptotic mechanisms involved in intestinal carcinoid tumor growth regulation...
  8. ncbi Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment
    Svetomir N Markovic
    Division of Hematology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:490-513. 2007
    ..Although much work remains to be done to improve the survival of patients with melanoma, clinically meaningful results seem within reach...
  9. ncbi Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors
    He Yu Zhang
    Department of Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocrine 30:299-306. 2006
    ..The other six genes did not show significant differences. These results suggest that increased methylation of RASSF1A and CTNNB1 may play important roles in progression and metastasis of small bowel carcinoid tumors...
  10. ncbi Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma
    Nobuki Nakamura
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocr Pathol 17:213-23. 2006
    ..These results indicate that some individual antibodies or a panel of antibodies combined with histopathological analysis can be useful in separating follicular adenoma (FA) from follicular variant of papillary thyroid carcinoma (FVPTC)...
  11. doi Papillary thyroid carcinoma with prominent hobnail features: a new aggressive variant of moderately differentiated papillary carcinoma. A clinicopathologic, immunohistochemical, and molecular study of eight cases
    Sofia Asioli
    Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Surg Pathol 34:44-52. 2010
    ..Two patients are alive without disease after 120 and 236 months. PTC with a prominent hobnail pattern is a moderately differentiated PTC variant with aggressive clinical behavior and significant mortality...
  12. ncbi In-transit melanoma: an individualized approach
    Travis E Grotz
    Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA
    Oncology (Williston Park) 25:1340-8. 2011
    ..Herein we present our institutional treatment algorithm, which allows for individualization based on the patient's presentation...
  13. ncbi RASSF1A and NORE1A methylation and BRAFV600E mutations in thyroid tumors
    Nobuki Nakamura
    Department of Laboratory Medicine and Pathology, Mayo Clinic Medical College, Rochester, MN 55905, USA
    Lab Invest 85:1065-75. 2005
    ..BRAF mutation occurs later in thyroid tumor progression and is restricted mainly to PTC and anaplastic thyroid carcinoma...
  14. doi Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression
    Sofia Asioli
    Division of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Mod Pathol 23:1269-78. 2010
    ..Expression of IMP3 appears to be an adverse prognostic factor for poorly differentiated thyroid carcinoma...
  15. doi Solid cell nests in Hashimoto's thyroiditis sharing features with papillary thyroid microcarcinoma
    Sofia Asioli
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Endocr Pathol 20:197-203. 2009
    ..These histological and immunophenotypic features can be used to distinguish SCN from papillary thyroid microcarcinomas associated with Hashimoto's thyroiditis...
  16. ncbi Galectin-4 expression in carcinoid tumors
    Kandelaria M Rumilla
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Endocr Pathol 17:243-9. 2006
    ..These results show a differential distribution of Gal-4 in carcinoid tumors in different locations of the gastrointestinal tract and the lungs...
  17. ncbi Oxyphil parathyroid carcinomas: a clinicopathologic and immunohistochemical study of 10 cases
    Lori A Erickson
    Department of Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Surg Pathol 26:344-9. 2002
    ..These findings also indicate that the same histopathologic features should be used to diagnose oxyphil and chief cell parathyroid carcinomas...
  18. pmc Mayo Clinic consensus recommendations for the depth of excision in primary cutaneous melanoma
    Travis E Grotz
    Department of Surgery, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 86:522-8. 2011
    ....
  19. pmc A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: an NCCTG Study
    Svetomir N Markovic
    Melanoma Study Group, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Am J Clin Oncol 31:573-9. 2008
    ..To improve the clinical and immunologic efficacy of therapy without compromising patient safety, we performed a further dose escalation trial in patients with metastatic melanoma...
  20. doi Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis
    Aaron S Mansfield
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mod Pathol 24:487-94. 2011
    ..These immunologic changes may explain the successful metastasis of melanoma in the midst of the immune environment of the sentinel lymph node, and lend insights into the mechanisms of lymphatic metastases in other solid malignancies...
  21. doi Mutant BRAF(T1799A) can be detected in the blood of papillary thyroid carcinoma patients and correlates with disease status
    Kendall W Cradic
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 1st Street SW, Rochester, Minnesota 55905, USA
    J Clin Endocrinol Metab 94:5001-9. 2009
    ..The BRAF(T1799A) transversion is the most frequent morphotype-specific somatic mutation in papillary thyroid carcinoma (PTC). The ability to detect this mutation in the circulation could aid in diagnosis and follow-up of PTC patients...
  22. pmc Circulating serologic and molecular biomarkers in malignant melanoma
    Shanique R Palmer
    Department of Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 86:981-90. 2011
    ....
  23. ncbi Galectin-3 expression in hyalinizing trabecular tumors of the thyroid gland
    Robyn L Gaffney
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Surg Pathol 27:494-8. 2003
    ..Our study suggests that the variable pattern of galectin-3 expression may reflect a difference in biologic behavior between HTT and papillary thyroid carcinoma...
  24. pmc Malignant melanoma in the 21st century: the emerging molecular landscape
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 83:825-46. 2008
    ..We review the emerging molecular landscape of melanoma and its implications for better management of patients with melanoma...
  25. ncbi A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma
    Svetomir N Markovic
    Department of Oncology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Am J Clin Oncol 30:303-9. 2007
    ..We conducted a phase II trial evaluating the clinical efficacy of ABT-510 and its effects on biomarkers of angiogenesis and immunity in patients with metastatic melanoma (MM)...
  26. ncbi Epidermal growth factor receptor and activated epidermal growth factor receptor expression in gastrointestinal carcinoids and pancreatic endocrine carcinomas
    Bettina Papouchado
    Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mod Pathol 18:1329-35. 2005
    ....
  27. ncbi Cdx2 as a marker for neuroendocrine tumors of unknown primary sites
    Lori A Erickson
    Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocr Pathol 15:247-52. 2004
    ..These results indicate that Cdx2 can be very useful in recognizing metastatic neuroendocrine carcinomas of unknown primary sites, especially when they are derived from the small intestine...
  28. ncbi Malignant melanoma in the 21st century, part 1: epidemiology, risk factors, screening, prevention, and diagnosis
    Svetomir N Markovic
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 82:364-80. 2007
    ..Part 2 (which will appear in the April 2007 issue) will review melanoma staging, prognosis, and treatment...
  29. doi Hyperinsulinemic hypoglycemia with nesidioblastosis: histologic features and growth factor expression
    Kandelaria M Rumilla
    Division of Anatomic Pathology, Mayo Clinic, Rochester, MN 55901, USA
    Mod Pathol 22:239-45. 2009
    ..These findings suggest that increased production of growth factors and growth factor receptors may contribute to the development of nesidioblastosis in adults...
  30. doi Primary cutaneous CD4-positive small/medium-sized pleomorphic T-cell lymphoma: a clonal T-cell lymphoproliferative disorder with indolent behavior
    Karen L Grogg
    Department of Laboratory Medicine and Pathology, Division of Anatomic Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Mod Pathol 21:708-15. 2008
    ..In patients with isolated cutaneous lesions, the indolent behavior of this rare T-cell neoplasm should be recognized to avoid unnecessary treatment...
  31. doi Metastatic malignant melanoma manifesting as an intracardiac mass
    Angela Wood
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
    Cardiovasc Pathol 19:153-7. 2010
    ..Antemortem diagnoses of intracardiac metastases are uncommon. Metastatic melanoma shows a propensity for cardiac involvement, but cardiac involvement by melanoma is rarely identified clinically due to a paucity of cardiac symptoms...
  32. ncbi Observer variation in the diagnosis of follicular variant of papillary thyroid carcinoma
    Ricardo V Lloyd
    Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Surg Pathol 28:1336-40. 2004
    ..Since most cases with metastatic disease had obvious invasion, caution should be used in making a diagnosis of FVPCA in the absence of the major histopathologic features or clear-cut invasive growth...
  33. pmc Ectopic low-grade adrenocortical carcinoma in the spinal region: immunohistochemical and molecular cytogenetic study of a pediatric case
    Fausto J Rodriguez
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 33:142-8. 2009
    ..This report demonstrates that ectopic adrenocortical tumors in the nervous system may exhibit clinicopathologic and cytogenetic features suggestive of adrenocortical carcinoma...
  34. pmc Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies
    David A Wada
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Mod Pathol 24:596-605. 2011
    ..Like all FISH studies, IRF4 testing must be interpreted in the context of morphology, phenotype, and clinical features...
  35. doi Prognostic features, human papillomavirus status, and epidermal growth factor receptor expression in oral squamous cell carcinoma in young adults
    Ligy Thomas
    Department of ENT, Mayo Clinic, Rochester, MN, USA
    Am J Otolaryngol 33:650-6. 2012
    ....
  36. ncbi Parathyroid lipoadenomas: a rare cause of primary hyperparathyroidism
    Lisa S Chow
    Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, College of Medicine, Rochester, Minnesota 55905, USA
    Endocr Pract 12:131-6. 2006
    ..To review one institution's experience with parathyroid lipoadenomas and to report the associated clinical characteristics...
  37. doi Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors
    Peter M Sadow
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Endocr Pathol 19:97-103. 2008
    ..These results show that stathmin is expressed at higher levels in more rapidly proliferating endocrine tumors. However, it is probably not useful as a stand-alone marker to determine malignancy in pheochromocytomas for individual tumors...
  38. ncbi Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 30-2002. An eight-year-old girl with fever, hemoptysis, and pulmonary consolidations
    Brian P O'Sullivan
    N Engl J Med 347:1009-17. 2002